GlassScriptPhysician profile
Anne Townsend Love
NPI 1649749797
$13,448.64
in general payments reported to CMS, 2019-2025
30 companies · $4,916 in 2025
The $4,916 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,445 · 2022: $2,420 · 2023: $1,430 · 2024: $3,238 · 2025: $4,916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,256 · Consulting Fee: $2,850 · Travel and Lodging: $288 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,256.00 |
| Consulting Fee | $2,850.00 |
| Travel and Lodging | $287.50 |
| Education | $189.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $3,158.32 | 2025 | Ebglyss |
| Incyte Corporation | $1,823.25 | 2021-2025 | Opzelura |
| Abbvie INC. | $933.52 | 2022-2025 | |
| Epi Health, LLC | $927.49 | 2022 | |
| Dermavant Sciences, INC. | $838.51 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $733.22 | 2023-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $721.28 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $603.55 | 2021-2025 | Dupixent |
| Genzyme Corporation | $549.47 | 2021-2025 | |
| Galderma Laboratories, L.P. | $332.21 | 2021-2025 | Aklief |
| Lilly USA, LLC | $314.27 | 2023-2025 | Olumiant, Ebglyss, Taltz |
| Leo Pharma INC. | $279.23 | 2021-2022 | |
| Organon LLC | $258.64 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $254.76 | 2021-2024 | Cabtreo, Jublia, Arazlo |
| Mayne Pharma Commercial LLC | $234.15 | 2022-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $234.07 | 2021-2023 | Puraply |
| Arcutis Biotherapeutics, INC. | $201.30 | 2024 | Zoryve |
| Sun Pharmaceutical Industries INC. | $199.78 | 2021-2024 | |
| Janssen Biotech, INC. | $188.07 | 2022-2025 | Tremfya |
| Pfizer INC. | $169.17 | 2021-2025 | |
| Vyne Pharmaceuticals INC. | $145.21 | 2021 | |
| Paratek Pharmaceuticals, INC. | $87.12 | 2025 | Nuzyra |
| Ucb, INC. | $62.98 | 2024-2025 | Bimzelx |
| Amgen INC. | $57.48 | 2022-2025 | Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $47.47 | 2024 | Entyvio |
| Boston Scientific Corporation | $23.65 | 2021 | |
| Biofrontera INC. | $23.46 | 2022 | |
| Bioventus LLC | $18.48 | 2022 | |
| Journey Medical Corporation | $15.02 | 2023 | |
| Verrica Pharmaceuticals INC. | $13.51 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Love listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.